Avanafil
  • A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction
    • Qnexa
  • SEQUEL trial American Journal of Clinical Nutrition
    • Qnexa
  • Weight Loss and Diabetic Status in Obese (BMI>35) Diabetic Adults after 56 Weeks on Phentermine/Topiramate CR (PHEN/TPM CR)
    		•
    Avanafil European Society of Sexual Medicine Meeting Posters, December 3, 2011
  • An Open-Label, Long-Term Evaluation of the Safety and Tolerability of Avanafil in Males With Erectile Dysfunction
  • Pharmacokinetics of Avanafil, a Novel, Rapidly Absorbed, Selective PDE5 Inhibitor for the Treatment of Mild to Severe Erectile Dysfunction
  • Avanafil, a Highly Selective Phosphodiesterase Type 5 Inhibitor for the Treatment of Erectile Dysfunction: Selectivity for Eleven PDE Isozymes, in Comparison With Sildenafil, Tadalafil and Vardenafil
    		•
    Avanafil Sexual Medicine Society North America 2011 Annual Meeting
  • A Phase III, Placebo-Controlled Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Nerve-Sparing Radical Prostatectomy
  • Avanafil, a Highly Selective Phosphodiesterase Type 5 Inhibitor for the Treatment of Erectile Dysfunction: Selectivity for Eleven PDE Isozymes, in Comparison With Sildenafil, Tadalafil and Vardenafil
  • Onset of Action and Time to Efficacy of Avanafil, a Novel, Rapid-Onset PDE5 Inhibitor in Men With Mild to Severe Erectile Dysfunction: Data From Phase 2 and Phase 3 Clinical Trials
    		•
    Qnexa EQUIP Study in Obesity Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
    Qnexa Obesity 2011: 29th Annual Scientific Meeting of The Obesity Society
  • Significant Weight Loss With Controlled-Release Phentermine/Topiramate Is Associated With Significant Reductions in Use of Concomitant Medications for Cardiometabolic Diseases Over 108 Weeks
  • Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate Correlates With Improvements in Liver Function in Overweight/Obese Adults With Elevated Alanine Aminotransferase
  • Severely Obese Adults Administered Controlled-Release Phentermine/Topiramate Maintained Their Weight Loss in the Second Year
    		•
    Qnexa American Neurology Association Annual Meeting, September 25-27, 2011 Retrospective Analysis of Major Congenital Malformations and Oral Clefts Associated With In Utero Topiramate Exposure
    Qnexa European Association for the Study of Diabetes, September 12-16, 2011
  • Long-term Glycaemic Effects of Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects With Diabetes
  • Decreased Progression to Diabetes in Subjects With Prediabetes After 2 Years of Treatment With Controlled-Release Phentermine/Topiramate
  • Long-term Weight Loss With Controlled-Release Phentermine/Topiramate Reverses Metabolic Syndrome and Improves Associated Traits
    		•
    Avanafil European Association for the Study of Diabetes, September 12-16, 2011 Treatment of Erectile Dysfunction in Men With Diabetes: Results of a Phase 3, Multicentre, Randomized, Controlled Trial of Avanafil
    Qnexa International Epilepsy Congress, Rome, August 31, 2011 Retrospective Analysis of Major Congenital Malformations (MCMs) and Oral Clefts (OC) Associated with In Utero Topiramate Exposure – Alison Pack, MD, MPH1; Kimford Meador, MD2; Arun Bhattacharyya, PhD3
    Qnexa American Diabetes Association (ADA) Meeting
  • Weight Loss with Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Reverses Metabolic Syndrome and Improves Associated Traits
  • Diabetes Prevention and Normalization of Fasting Glucose in Subjects with Prediabetes Using Controlled-Release Phentermine/Topiramate in a 2-Year Weight Loss Intervention
  • Long-Term Weight Loss and Improvement in Glycemic Parameters with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)
    		•
    Qnexa 51st Annual Meeting of the Teratology Society Assessment of the Teratogenic Risk in Fetuses Exposed to Topiramate in Utero
    Qnexa American Society of Hypertension Evaluation of Cardiovascular Effects in Three Double-Blind, Placebo-Controlled Clinical Trials with Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)
    Avanafil Cancer Survivor Symposium
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral, Nerve-Sparing Radical Prostatectomy
    		•
    Qnexa European Congress on Obesity, 2011
  • Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate Therapy Improves Glycaemic Status and Prevents Progression to Type 2 Diabetes Mellitus
  • Long-term Treatment With Controlled-Release Phentermine/Topiramate Demonstrates Sustained Weight Loss Over 108 Weeks
  • Cardiometabolic Risk Reduction is Directly Related to Magnitude of Weight Loss. A Study Using an Investigational Weight Loss Combination Phentermine/Topiramate CR
  • Efficacy and Tolerability of Topiramate Alone and in Combination With Phentermine
    		•
    Avanafil Avanafil presentation at American Urological Assocation TA-314, Long-term safety study
    Qnexa QNEXA Lancet publication
  • Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Kishore M Gadde, David B Allison, Donna H Ryan, Craig A Peterson, Barbara Troupin, Michael L Schwiers, Wesley W Day

    • QNEXA Lancet Supplementary webappendix
  • Supplementary webappendix
    		•
    Qnexa American College of Cardiology Weight Loss and Cardiovascular Risk Reduction Over 2 Years with Controlled-Release Phentermine-Topiramate
    Qnexa Society of Toxicology Annual Meeting, March 7, 2011 Topiramate and Birth Defects:An Update
    Qnexa The Obesity Society's Annual Scientific Meeting
  • Low-Dose, Controlled-Release Phentermine/Topiramate Reduces Hunger and Increases Satiety, Leading to Weight Loss in Overweight/Obese Adults
  • Clinically Meaningful Weight-Loss Outcomes With Low-Dose Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects
  • Low-Dose, Controlled-Release Phentermine/Topiramate Reduces Adiposity, Improves Cardiometabolic Risk in Overweight/Obese Patients
  • Low-Dose Controlled-Release Phentermine/Topiramate for Weight Loss and Management of Type 2 Diabetes Mellitus
  • Weight Loss With Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Improves Plasma Alanine Transaminase Concentrations
  • Improvements in Quality of Life With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects
    		•
    Qnexa European Society of Cardiology Congress
  • Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) Mediated Weight Loss Causes Improvement in Lipoproteins and Inflammatory Biomarkers in Overweight Patients With Comorbidities
  • Low-Dose, Controlled-Release Phentermine/Topiramate Mediated Weight Loss Causes Improvements in Lipoproteins and Inflammatory Biomarkers in Overweight Patients With Comorbidities
  • Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM) Improves Cardiovascular Disease (CVD) Risk Factors
  • Low-Dose, Controlled-Release Phentermine/Topiramate Improves Cardiovascular Disease Risk Factors
    		•
    Qnexa American Diabetes Association 70th Scientific Sessions
  • Magnitude of Weight Loss Experienced With a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate May Drive Degree of Cardiometabolic Benefit
  • Improvements in Dyslipidemia and Other Cardiometabolic Disease Risk Factors With Low-Dose, Controlled-Release Phentermine/Topiramate
  • Changes in Insulin Sensitivity and Insulin Secretion in Overweight/Obese Patients Treated With Low-Dose, Controlled-Release Phentermine/Topiramate
  • Low-Dose, Controlled-Release Phentermine/Topiramate and Markers of Type 2 Diabetes Mellitus
  • Effects of Low-Dose, Controlled-Release Phentermine/Topiramate on Weight, Glycemic Markers, and Progression to Type 2 Diabetes Mellitus
  • A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients With Type 2 Diabetes Mellitus or Prediabetes: the CONQUER Trial
  • Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs Non-African American Subjects: Pooled 1-Year Data From Two Phase 3 Trials
    		•
    Associated Professional Sleep Societies A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Phentermine/Topiramate CR (VI-0521) for the Treatment of Obstructive Sleep Apnea/Hypopnea Syndrome in Obese Adults
    Avanafil American Urological Assocation 2010 Annual Meeting Investigating Avanafil in the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled Clinical Trial
  • Qnexa 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) - May 15, 2010 Weight Loss With Controlled-Release Phentermine-Topiramate (PHEN/TPM CR) Drives Improvements in Obesity-Related Comorbidities in Overweight and Obese Subjects Over 12 Months Treatment
  • Qnexa EuroPRevent 2010 - May 5, 2010
  • 12-Month Weight Loss and Triglyceride Changes With PHEN/TPM CR in Overweight and Obese Subjects With Hypertriglyceridemia
  • 12-Month Weight Loss and Antihypertensive Benefits With PHEN/TPM CR in Overweight and Obese Subjects With Hypertension
    		•
    Qnexa American Society of Hypertension 25th Annual Scientific Meeting and Exposition - May 4, 2010 Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Improves Blood Pressure and Results in Weight Loss in Overweight/Obese Patients Through 28 Weeks
  • Qnexa EASD EASD Presentation in Vienna – October 2, 2009
    Qnexa Qnexa Phase 3 Results Conference Call – September 9, 2009
    Qnexa ADA
    		 Weight Loss with VI-0521 Stops Progression Toward Type 2 Diabetes in Obese Non-diabetic Subjects – June, 2009
    Qnexa ADA Can Weight Loss Treat Diabetes? Results of One-Year of Treatment with VI-0521 in Obese Type 2 Diabetics – June, 2009
    Qnexa NAASO Long-Term Follow-Up of Phentermine with Topiramate for Obesity in Clinical Practice
    Qnexa NAASO Changes in Weight and Quality of Life in Obese Adults Treated with Topiramate Plus Phentermine
    Qnexa ADA The Weight Effects of VI-0521 in Type 2 Diabetes
    Qnexa ADA Effect of VI-0521 (Phentermine and Topiramate) in Type 2 Diabetes (Abstract)
    Avanafil SMSNA Safety and Efficacy of Avanafil, A new PDE5 Inhibitor for Treating Erectile Dysfunction
    Avanafil SMSNA Hemodynamic Effects of Co-Administration of Avanafil and Glyceryl Trinitrate
    Avanafil SMSNA Pharacokinetics of Avanafil, a New PDE5 Inhibitor Being Developed for Treating Erectile Dysfunction
    PDF Print E-mail  
    © 2012 VIVUS Inc. All rights reserved...